License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) performance_obligation	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	$ 48,964,000	$ 48,756,000	$ 237,422,000	$ 153,973,000
Deferred revenue	44,561,000		44,561,000
Revenue recognized	5,047,000	9,159,000	29,574,000	20,363,000
Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable	1,870,000	21,413,000	1,870,000	21,413,000	$ 19,094,000	$ 3,045,000
Mitsubishi Tanabe Pharma Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			2,400,000
Mitsubishi Tanabe Pharma Corporation | License Collaboration And Other Revenue, Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	400,000	300,000	1,200,000	400,000
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue			$ 25,000,000
Mitsubishi Tanabe Pharma Corporation | MTPC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations | performance_obligation			2
Deferred revenue	1,265,000		$ 1,265,000
Mitsubishi Tanabe Pharma Corporation | MTPC Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue			15,000,000
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received			20,000,000
Cost of research services			20,500,000
Milestone revenue			10,000,000
Accounts receivable	0		0
Deferred revenue	0		0
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue			10,000,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable	200,000		200,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized	5,100,000	$ 2,200,000	12,700,000	$ 6,700,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	200,000		200,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Contract With Customer, Liability
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	1,300,000		1,300,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Other Current Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	$ 18,600,000		$ 18,600,000